Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Pharmacogenomics ; 18(10): 981-985, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28639487

ABSTRACT

AIM: To investigate the potential involvement of the hepatic ATP-binding cassette transporters MRP2 and MDR1 in the disposition of lumefantrine (LUM) among patients with uncomplicated Plasmodium falciparum malaria. MATERIALS & METHODS: The tag SNPs MDR1/ABCB1 C3435T and MRP2/ABCC2 C1515Y were determined in two artemether-LUM clinical trials, including a pharmacokinetic/pharmacodynamic study focused on the treatment phase (72 h), and an efficacy trial where day 7 (D7) LUM levels were measured. RESULTS: The 1515YY genotype was significantly associated with higher (p < 0.01) LUM D7 concentrations (median 1.42 µM), compared with 0.77 µM for 1515CY and 0.59 µM for 1515CC. No significant influence of the MDR1/ABCB1 C3435T was found. CONCLUSION: LUM body disposition may be influenced by MRP2/ABCC2 genotype.


Subject(s)
Antimalarials/pharmacokinetics , Artemisinins/pharmacokinetics , Ethanolamines/pharmacokinetics , Fluorenes/pharmacokinetics , Malaria, Falciparum/drug therapy , Multidrug Resistance-Associated Proteins/genetics , Polymorphism, Single Nucleotide , Antimalarials/administration & dosage , Antimalarials/blood , Area Under Curve , Artemether , Artemisinins/administration & dosage , Artemisinins/blood , Child , Child, Preschool , Drug Combinations , Ethanolamines/administration & dosage , Ethanolamines/blood , Fluorenes/administration & dosage , Fluorenes/blood , Genotype , Humans , Lumefantrine , Malaria, Falciparum/genetics , Multidrug Resistance-Associated Protein 2 , Pharmacogenomic Variants , Tissue Distribution
2.
Antimicrob Agents Chemother ; 59(1): 96-104, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25313206

ABSTRACT

Malaria patients are frequently coinfected with HIV and mycobacteria causing tuberculosis, which increases the use of coadministered drugs and thereby enhances the risk of pharmacokinetic drug-drug interactions. Activation of the pregnane X receptor (PXR) by xenobiotics, which include many drugs, induces drug metabolism and transport, thereby resulting in possible attenuation or loss of the therapeutic responses to the drugs being coadministered. While several artemisinin-type antimalarial drugs have been shown to activate PXR, data on nonartemisinin-type antimalarials are still missing. Therefore, this study aimed to elucidate the potential of nonartemisinin antimalarial drugs and drug metabolites to activate PXR. We screened 16 clinically used antimalarial drugs and six major drug metabolites for binding to PXR using the two-hybrid PXR ligand binding domain assembly assay; this identified carboxymefloquine, the major and pharmacologically inactive metabolite of the antimalarial drug mefloquine, as a potential PXR ligand. Two-hybrid PXR-coactivator and -corepressor interaction assays and PXR-dependent promoter reporter gene assays confirmed carboxymefloquine to be a novel PXR agonist which specifically activated the human receptor. In the PXR-expressing intestinal LS174T cells and in primary human hepatocytes, carboxymefloquine induced the expression of drug-metabolizing enzymes and transporters on the mRNA and protein levels. The crucial role of PXR for the carboxymefloquine-dependent induction of gene expression was confirmed by small interfering RNA (siRNA)-mediated knockdown of the receptor. Thus, the clinical use of mefloquine may result in pharmacokinetic drug-drug interactions by means of its metabolite carboxymefloquine. Whether these in vitro findings are of in vivo relevance has to be addressed in future clinical drug-drug interaction studies.


Subject(s)
Cytochrome P-450 CYP2B6 Inducers/pharmacology , Mefloquine/analogs & derivatives , Mefloquine/metabolism , Receptors, Steroid/agonists , Animals , Antimalarials/metabolism , Biological Transport/drug effects , COS Cells , Cell Line , Chlorocebus aethiops , Cytochrome P-450 CYP2B6/metabolism , Drug Interactions , Drug Resistance , Hep G2 Cells , Hepatocytes , Humans , Malaria/drug therapy , Mefloquine/pharmacology , Mefloquine/therapeutic use , Pregnane X Receptor , Protein Binding , RNA Interference , RNA, Small Interfering , Receptors, Steroid/genetics , Receptors, Steroid/metabolism
3.
Antimicrob Agents Chemother ; 56(4): 2153-7, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22252826

ABSTRACT

Artemisinins induce drug metabolism through the activation of the pregnane X receptor (PXR) in vitro. Here, we report the resequencing and genotyping of PXR variants in 75 Vietnamese individuals previously characterized for CYP3A enzyme activity after artemisinin exposure. We identified a total of 31 PXR variants, including 5 novel single nucleotide polymorphisms (SNPs), and we identified significantly different allele frequencies relative to other ethnic groups. A trend of significance was observed between the level of CYP3A4 induction by artemisinin and two PXR variants, the 8118C→T (Y328Y) and 10719A→G variants.


Subject(s)
Antimalarials/pharmacology , Artemisinins/pharmacology , Cytochrome P-450 CYP3A/biosynthesis , Receptors, Steroid/genetics , 3' Untranslated Regions/genetics , Alleles , Cytochrome P-450 CYP3A/genetics , DNA Primers , Enzyme Induction/drug effects , Gene Frequency , Genetic Variation , Humans , Pharmaceutical Preparations/metabolism , Polymorphism, Single Nucleotide , Pregnane X Receptor , Receptors, Steroid/drug effects , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Vietnam/epidemiology
4.
Malar J ; 10: 376, 2011 Dec 19.
Article in English | MEDLINE | ID: mdl-22183028

ABSTRACT

BACKGROUND: In Honduras, chloroquine and primaquine are recommended and still appear to be effective for treatment of Plasmodium falciparum and Plasmodium vivax malaria. The aim of this study was to determine the proportion of resistance associated genetic polymorphisms in P. falciparum and P. vivax collected in Honduras. METHODS: Blood samples were collected from patients seeking medical attention at the Hospital Escuela in Tegucigalpa from 2004 to 2006 as well as three regional hospitals, two health centres and one regional laboratory during 2009. Single nucleotide polymorphisms in P. falciparum chloroquine resistance transporter (pfcrt), multidrug resistance 1 (pfmdr1), dihydrofolate reductase (pfdhfr) and dihydropteroate synthase (pfdhps) genes and in P. vivax multidrug resistance 1 (pvmdr1) and dihydrofolate reductase (pvdhfr) genes were detected using PCR based methods. RESULTS: Thirty seven P. falciparum and 64 P. vivax samples were collected. All P. falciparum infections acquired in Honduras carried pfcrt, pfmdr1, pfdhps and pfdhfr alleles associated with chloroquine, amodiaquine and sulphadoxine-pyrimethamine sensitivity only. One patient with parasites acquired on a Pacific Island had pfcrt 76 T and pfmdr1 86Y alleles. That patient and a patient infected in West Africa had pfdhfr 51I, 59 R and 108 N alleles. Pvmdr1 976 F was found in 7/37 and two copies of pvmdr1 were found in 1/37 samples. Pvdhfr 57 L + 58 R was observed in 2/57 samples. CONCLUSION: The results indicate that P. falciparum from Honduras remain sensitive to chloroquine and sulphadoxine-pyrimethamine. This suggests that chloroquine and sulphadoxine-pyrimethamine should be efficacious for treatment of uncomplicated P. falciparum malaria, supporting current national treatment guidelines. However, genetic polymorphisms associated with chloroquine and sulphadoxine-pyrimethamine tolerance were detected in local P. vivax and imported P. falciparum infections. Continuous monitoring of the prevalence of drug resistant/tolerant P. falciparum and P. vivax is therefore essential also in Honduras.


Subject(s)
Antimalarials/pharmacology , Drug Resistance , Malaria, Falciparum/parasitology , Malaria, Vivax/parasitology , Plasmodium falciparum/genetics , Plasmodium vivax/genetics , Polymorphism, Single Nucleotide , Chloroquine/pharmacology , Honduras , Humans , Plasmodium falciparum/drug effects , Plasmodium falciparum/isolation & purification , Plasmodium vivax/drug effects , Plasmodium vivax/isolation & purification , Primaquine/pharmacology , Protozoan Proteins/genetics
5.
Expert Opin Drug Metab Toxicol ; 7(10): 1185-200, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21899476

ABSTRACT

INTRODUCTION: Plasmodium falciparum malaria is one of the world's most lethal infectious diseases, commanding millions of drug administrations per year. The pharmacogenetics of these drugs is poorly known, although its application can be pivotal for the optimized management of this disease. AREAS COVERED: The main components of artemisinin combination therapy (ACT), the worldwide main antimalarial strategy, are metabolized by the polymorphic CYP3A4 (mefloquine, artemether, lumefantrine), CYP2C8 (amodiaquine), CYP2A6 (artesunate) and CYP1A1/2 (amodiaquine/desethylamodiaquine), with dihydroartemisinin being acted by Phase II UDP-glucuronosyltransferases. The worldwide adoption of ACT is leading to a large number of antimalarial treatments. Simultaneously, the feared development of parasite drug resistance might drive dosing increases. In these scenarios of increased drug exposure, pharmacogenetics can be a key tool supporting evidence-based medicine aiming for the longest possible useful lifespan of this important chemotherapy. EXPERT OPINION: Translation in this moment is not operationally possible at an individual level, but large population studies are achievable for: i) the development of robust pharmacogenetics markers; and ii) the parallel development of a pharmacogenetic cartography of malaria settings. Advances in the understanding of antimalarial pharmacogenetics are urgent in order to protect the exposed populations, enhance the effectiveness of ACT and, consequently, contributing for the long aimed elimination of the disease.


Subject(s)
Antimalarials/therapeutic use , Artemisinins/therapeutic use , Malaria, Falciparum/drug therapy , Pharmacogenetics/methods , Aminoquinolines/chemistry , Aminoquinolines/therapeutic use , Antimalarials/chemistry , Artemisinins/chemistry , Artesunate , Aryl Hydrocarbon Hydroxylases/genetics , Aryl Hydrocarbon Hydroxylases/metabolism , Cytochrome P-450 CYP2A6 , Cytochrome P-450 CYP2C8 , Cytochrome P-450 CYP3A/genetics , Cytochrome P-450 CYP3A/metabolism , Drug Combinations , Drug Resistance , Ethanolamines/chemistry , Ethanolamines/therapeutic use , Evidence-Based Medicine , Fluorenes/chemistry , Fluorenes/therapeutic use , Genetic Markers , Humans , Lumefantrine , Malaria, Falciparum/parasitology , Mefloquine/chemistry , Mefloquine/therapeutic use , Plasmodium falciparum/drug effects , Polymorphism, Single Nucleotide
6.
Clin Chem Lab Med ; 44(2): 168-70, 2006.
Article in English | MEDLINE | ID: mdl-16475901

ABSTRACT

Cytochrome P450 2C8 (CYP2C8) is a polymorphic phase I drug-metabolising enzyme involved in the metabolism of a wide variety of xenobiotics, as well as a proposed player in the regulation of vascular tone. Polymorphisms in this gene may have an impact on the metabolism of therapeutic drugs such as paclitaxel and verapamil. In this report we have determined the frequencies of the main non-synonymous CYP2C8 alleles, 805A>T (CYP2C8*2), 416G>A/1196A>G (CYP2C8*3) and 792C>G (CYP2C8*4) in a sample representative of Portuguese Caucasians. The allelic frequencies determined were 1.2%, 19.8%, and 6.4% for CYP2C8*2, CYP2C8*3, and CYP2C*4, respectively. The observed CYP2C8*3 prevalence is significantly different from the frequencies previously reported in North European populations.


Subject(s)
Aryl Hydrocarbon Hydroxylases/genetics , Polymorphism, Genetic , Alleles , Cytochrome P-450 CYP2C8 , Female , Gene Frequency , Humans , Male , Portugal/epidemiology , White People/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...